Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VMCL for advanced stage IV melanoma
ACTRN12605000425695Phase 2Active, not recruiting
- Sponsor
- Royal Adelaide Hospital
- Start
- Jan 2000
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of vaccinia melanoma cell lysate vaccine in melanoma, sponsored by Royal Adelaide Hospital. Primary endpoints: Efficacy and Overall survival. Started Jan 2000; status: active, not recruiting.
02
Drugs
vaccinia melanoma cell lysate vaccine
03
Conditions
melanoma
Beyond the preview
Go deeper on ACTRN12605000425695.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12605000425695.